Delores Schendel, Medigene CEO (Vimeo via website)
Medigene cuts TCR-T therapy in pivot to focus on solid tumors
It’s been several months since Medigene AG laid out plans to devote itself to solid tumors. In keeping with that promise, the German biotech said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
